In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution by Angheloiu, Alexandra A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2020-09-01 
In-Vitro Sorbent-Mediated Removal of Edoxaban from Human 
Plasma and Albumin Solution 
Alexandra A. Angheloiu 
Temple University 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Fluids and Secretions Commons, Hemic and Immune Systems Commons, Investigative 
Techniques Commons, Laboratory and Basic Science Research Commons, and the Pharmaceutical 
Preparations Commons 
Repository Citation 
Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. (2020). In-Vitro Sorbent-Mediated Removal of 
Edoxaban from Human Plasma and Albumin Solution. Open Access Articles. https://doi.org/10.1007/
s40268-020-00308-1. Retrieved from https://escholarship.umassmed.edu/oapubs/4354 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Vol.:(0123456789)
Drugs in R&D (2020) 20:217–223 
https://doi.org/10.1007/s40268-020-00308-1
ORIGINAL RESEARCH ARTICLE
In‑Vitro Sorbent‑Mediated Removal of Edoxaban from Human Plasma 
and Albumin Solution
Alexandra A. Angheloiu1 · Yanglan Tan2,3 · Cristian Ruse4 · Scott A. Shaffer2,3 · George O. Angheloiu5 
Published online: 15 May 2020 
© The Author(s) 2020
Abstract
Background and Objective Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast 
agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist 
direct oral anticoagulant.
Methods We circulated 100 mL of edoxaban solution during six first-pass cycles through 40-mL sorbent columns (containing 
either CytoSorb in three passes or Porapak Q 50–80 mesh in the remaining three passes) during experiments using human 
plasma and 4% bovine serum albumin solution as drug vehicles. Drug concentration was measured by liquid chromatography-
tandem mass spectrometry.
Results Edoxaban concentration in two experiments performed with human plasma dropped from 276.8 to 2.7 ng/mL and 
undetectable concentrations, respectively, with CytoSorb or Porapak Q 50–80 mesh (p = 0.0031). The average edoxaban 
concentration decreased from 407 ng/mL ± 216 ng/mL to 3.3 ng/mL ± 7 ng/mL (p = 0.017), for a removal rate of 99% across 
all six samples of human plasma (two samples) and bovine serum albumin solution (four samples). In four out of the six 
adsorbed samples, the drug concentrations were undetectable.
Conclusion Sorbent-mediated technology may represent a viable pathway for edoxaban removal from human plasma or 
albumin solution.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 8-020-00308 -1) contains 
supplementary material, which is available to authorized users.
 * George O. Angheloiu 
 angheloiug@upmc.edu; angheloiu1@yahoo.com
1 Temple University, Philadelphia, PA, USA
2 Mass Spectrometry Facility, University of Massachusetts 
Medical School, Shrewsbury, MA, USA
3 Biochemistry and Molecular Pharmacology, University 
of Massachusetts Medical School, Worcester, MA, USA
4 New England Biolabs, Ipswich, MA, USA
5 Cardiology Department, University of Pittsburgh Medical 
Center, 700 High Street, Williamsport, PA 17701, USA
Key Points 
Porapak Q 50–80 mesh and CytoSorb are two sorbents 
that remove 99% of edoxaban from human plasma and 
bovine serum albumin solutions.
In several samples, the adsorbed edoxaban concentration 
was non-detectable.
In our set of experiments, we achieved complete removal 
in a minimum of 15 min.
1 Introduction
The American Heart Association estimates that at least 6.1 
million Americans are currently diagnosed on a yearly basis 
with atrial fibrillation [1]. A novel class of anticoagulants 
currently widely used in patients with atrial fibrillation are 
factor Xa antagonists, such as edoxaban. This article dem-
onstrates a sorbent methodology of edoxaban removal from 
human plasma and bovine serum albumin (BSA), as an alter-
native to edoxaban antidotes [2].
Edoxaban is a novel anticoagulant acting reversibly on 
factor Xa with a clinical half-life of approximately 10–14 h 
and has been demonstrated to be non-inferior to warfarin in 
protecting against strokes or systemic embolism in patients 
with atrial fibrillation [3]. In the venous thromboembolism 
treatment Hokusai-VTE trial comparing edoxaban with 
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warfarin, the rate of major or clinically relevant non-major 
bleeding was 8.5% with edoxaban vs 10.3% for warfarin 
(p = 0.004 for superiority) [4].
Based on previous experience of sorbent-mediated tica-
grelor, dabigatran, and radiocontrast agent removal, we set 
out in this study to test the effect of two sorbents, CytoSorb 
and Porapak Q 50–80 mesh on the removal of edoxaban 
from human plasma and 4% BSA solution [5–9]. Our investi-
gation does not intend to compare the adsorptive capacity of 
the two sorbents but merely to prove that removing edoxaban 
is a property of the sorbent family.
2  Methods
2.1  Definitions
Drug removal is the ratio expressed as a percentage of the 
difference between the affluent concentration (baseline) and 
the effluent concentration (adsorbed) divided by the affluent 
concentration. The filtration velocity expressed as output in 
mL/min represents the velocity of the fluid vehicle (human 
plasma or BSA solution) carrying the drug through the sorb-
ent column.
2.2  Vehicle Solutions
A stock edoxaban solution was obtained by mixing pure 
edoxaban powder (donated by Daiichi Sankyo, Nihonbashi, 
Tokyo, Japan) with 4% BSA solution in normal saline, gen-
erating a concentration of 100 µg/mL of edoxaban. Human 
plasma was obtained from blood donated by a healthy 
volunteer in sodium citrate vacutainers and centrifuged 
at 5600 rpm for 5 min. Plasma was separated and frozen 
at – 20 °C between collection and experiments. The final 
adsorbed samples were frozen at − 80 °C until concentration 
measurements were performed, and shipped in dry ice to the 
mass spectrometry laboratory.
Human plasma and 4% BSA baseline solution with an 
edoxaban target concentration of 100 ng/mL (higher than 
48.5 ng/mL, the mean therapeutic concentration of edoxa-
ban in patients allocated to the dose of 60 mg/day in the 
ENGAGE atrial fibrillation trial) was generated prior 
to experiments by mixing the stock solution with human 
plasma or 4% BSA. A local institutional review board 
exemption was obtained for completing the study.
2.3  System
We studied edoxaban removal by CytoSorb (Cytosorb-
ents, Monmouth Junction, NJ, USA) and Porapak Q 50–80 
mesh (Supelco, Bellefonte, PA, USA) in a first-pass manner 
(injected from a syringe and then collected in a jar without 
recirculating the vehicle solution; Fig. 1). Each sorbent was 
injected during three first-pass trials. One hundred millilit-
ers of solution were manually injected into the two types of 
sorbents’ columns using 60-mL volume syringes and clear 
plastic tubing. We used medical-grade tubing and syringes 
and thus did not expect any edoxaban adsorption from them. 
The drug-vehicle solution mix was circulated through the 
columns in an anti-gravitational fashion.
2.4  First‑Pass Experiments
There were a total of six first passes performed by passing 
the effluent solution through 40 mL of sorbent. We used 
increasing filtration velocities at increasingly shorter experi-
mental adsorption times, to assess the minimum necessary 
adsorption time.
Two trials used human plasma as a vehicle by passing 
the drug-plasma mix through the two types of sorbents for 
30 min (velocity 3.3 mL/min). Four passes used BSA-edoxa-
ban (two passes for each sorbent). In two BSA-edoxaban 
experiments, the drug-vehicle mix was passed for a dura-
tion of 15 min through the two types of sorbents and in two 
other passes for 60 min (at velocities of 6.7 and 1.7 mL/min, 
respectively).
2.4.1  Edoxaban Concentration Measurement Assay
Edoxaban concentration was assessed using liquid chroma-
tography-tandem mass spectrometry.
2.4.2  Sample Preparation
A stock solution of edoxaban was prepared in methanol at 
concentrations of 1.00 mg/mL. Serial dilutions were made 
with blank 4% BSA to prepare calibrated standard solu-
tions at the concentrations of 0.5–800 ng/mL. The internal 
Fig. 1  Experimental set-up
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standard solution was prepared using diazepam in methanol/
water (1:1, v:v) at a diazepam concentration of 100 ng/mL.
Calibration samples were prepared in duplicate by mixing 
50 µL of each calibrate standard solution and 10 µL of inter-
nal standard solution. After adding 150 µL of acetonitrile 
containing 1.0% (v/v) formic acid and vortexing for 1 min, 
the samples were centrifuged (16,000g, 10 min) and 100 µL 
of supernatant was collected for liquid chromatography-tan-
dem mass spectrometry analysis. Study samples were also 
prepared in duplicate by following the procedures above.
2.4.3  Liquid Chromatography–Tandem Mass Spectrometry 
Analysis
Two microliters of samples were injected into a Thermo Sci-
entific Ultimate 3000 HPLC system coupled with a Thermo 
Scientific TSQ Quantiva triple quadrupole mass spectrometer. 
The chromatographic separation was performed on a Waters 
Acquity BEH C18 column (1.7 µm, 2.1 × 100 mm). The col-
umn oven temperature was maintained at 25 °C. The mobile 
phase consisted of water containing 0.1% formic acid (A) and 
acetonitrile (B) and pumped at a flow rate of 0.25 mL/min. 
The gradient conditions were set as follows: 0 min, 20% B, 
1.0 min, 20% B, 6.0 min, 95% B, 10.0 min, 95% B, 10.1 min, 
20% B, 15.0 min, 20% B, giving a total 15-min run.
Ionization was operated in the positive mode (voltage, 
3.8 kV). The parameters were set as follows: sheath gas, 
40 Arb; aux gas, 15 Arb; vaporizer temperature, 250 °C; 
ion transfer tube temperature, 325 °C. Multiple reaction 
monitoring was performed using a cycle time of 0.3 s, CID 
gas pressure of 1.5 mTorr, Q1 resolution (full width at half 
maximum) of 0.7 and Q3 resolution (full width at half 
maximum) of 0.7. The multiple reaction monitoring transi-
tions, m/z 548.2 > 366.1 (CE 18.4 V) for edoxaban and m/z 
285.1 > 193.1 (CE 31.4 V) for diazepam were selected and 
used for quantitation.
2.4.4  Data Analysis
The retention times for edoxaban and diazepam were 3.7 min 
and 5.4 min, respectively. All data were integrated and pro-
cessed in Xcalibur (Version 2.2; Thermo Scientific, San 
Jose, CA). Edoxaban was quantified based on the peak area 
ratio to diazepam. Calibration curves were constructed by 
plotting the peak area ratios as a function of concentration. 
Origin was excluded and a 1/X2 axis weighting was applied. 
A good linear dynamic range was obtained between 0.5 and 
800 ng/mL, and the detection limit was 0.1 ng/mL.
2.4.5  Statistics
Mean values were compared using the paired Student t test, 
using a Microsoft Office 2016 Excel spreadsheet.
3  Results
The average baseline concentration of edoxaban in the 
six samples of human plasma and BSA solution was 
407 ± 216 ng/mL with a drop to a value of 3.3 ± 7 ng/mL 
after adsorption (p = 0.006; Fig. 2a; Table 1). The baseline 
average concentration in the human plasma samples was 
276.8 ng/mL. After adsorption, the concentration in human 
plasma dropped to 1.35 ± 1.9 ng/mL (p = 0.003; Fig. 2b; 
Table 1).
The rate of edoxaban removal was 99.5% in human 
plasma and 99% across all six samples (Fig. 3). The aver-
age baseline concentrations with Porapak Q 50–80 mesh 
and CytoSorb were 490 ± 185 ng/mL and 325 ± 251 ng/mL 
while the adsorbed values were 0 ng/mL and 6.7 ± 9 ng/mL, 
respectively (p < 0.001 for both comparisons; Table 1).
The shortest run lasted 15 min. In this experiment we 
succeeded to decrease the edoxaban concentration from 
593.6 ng/mL to non-detectable concentrations and 17 ng/
mL, with removal rates of 100% for Porapak Q 50–80 mesh 
and 97% for CytoSorb repectively.
4  Discussion
Edoxaban was non-inferior to warfarin in the ENGAGE AF-
TIMI trial with respect to the prevention of stroke or sys-
temic embolism and was associated with significantly lower 
rates of bleeding and death from cardiovascular causes [3]. 
While the yearly risk of major bleeding was higher with war-
farin (3.43%), the bleeding risk with a high dose of 60 mg/
day of edoxaban (2.75%) was not insignificant [1].
We presented in this study an efficient method to remove 
edoxaban both from human plasma and 4% BSA solution 
in a series of six bench experiments. In human plasma 
experiments, the drug average concentration decreased from 
276.8 to 1.4 ng/mL (Fig. 2b), for a removal rate of 99.5% 
(p = 0.0031; Fig. 3). We were able to decrease the average 
concentration in the pooled series of samples from 407 ng/
mL ± 216 ng/mL to 3.3 ng/mL ± 7 ng/mL (Fig. 2a).
4.1  Clinical Significance
The average baseline edoxaban concentration in the human 
plasma and pooled samples (276.8 and 407 ng/mL) was 
higher than the highest mean concentration of 48.5 ng/mL 
corresponding to the 60-mg/day dose used in ENGAGE 
AF-TIMI, and comparable to the peak plasma concen-
tration of 256 ng/mL after one oral 60-mg dose [9, 10]. 
The adsorbed final concentrations were much lower than 
these values [10]. All adsorbed edoxaban concentrations 
obtained with Porapak Q 50–80 mesh and those resulting 
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from 60-min CytoSorb removal were undetectable, hence 
they were lower than the half maximal inhibitory concen-
tration for anti-Xa activity of edoxaban of 3 nM or 1.6 ng/
mL [10].
Both sorbents showed excellent removal capacity even 
with very short circulating times. While running the first-
pass circuit for only 15 min, we obtained removal rates of 
100% in 4% BSA for Porapak Q 50–80 mesh and 97% for 
CytoSorb (average 99%), succeeding to decrease the edoxa-
ban concentration from 593.6 ng/mL to non-detectable 
concentrations and 17 ng/mL, respectively. As we obtained 
99% removal with high velocities, it is possible that similar 
removal rates can be obtained with even shorter circulation 
times.
We recently achieved excellent results in sorbent removal 
of antiplatelet medications such as ticagrelor, direct throm-
bin inhibitor anticoagulants such as dabigatran, as well as 
radiocontrast agents commonly used in cardiac catheteriza-
tion procedures [5–8]. Our current findings along with pre-
viously presented results may allow sorbent technology to 
become an important tool in avoiding or treating important 
side effects of agents commonly used in day-by-day clinical 
cardiology work.
Fig. 2  Concentration of edoxaban in the six samples of human 
plasma (two samples) and bovine serum albumin (BSA) solu-
tion (four samples) as measured by liquid chromatography-tandem 
mass spectrometry before (baseline concentration) and after sorbent 
adsorption (adsorbed concentration) (a); average concentration of 
edoxaban in human plasma before and after sorbent adsorption (b)
Table 1  Baseline and adsorbed edoxaban concentrations in two sam-
ples of human plasma (column 1), across all six samples (column 2), 
and in samples passed through Porapak Q 50–80 mesh (column 3) 
and CytoSorb (column 4)
Human 
plasma












1.4 ± 1.9 3.3 ± 7 0 6.7 ± 9
P value 0.003 0.01  < 0.001  < 0.001
Fig. 3  Average removal rate of 
edoxaban across all six samples 
(a), in human plasma [two 
samples (b)] and comparatively 
CytoSorb for three samples and 
Porapak Q 50–80 mesh column 
for the remaining three samples 
(c)
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Sorbents, such as Porapak Q 50–80 mesh and CytoSorb, 
are widely used in the industry and the household environ-
ment (most recognizable in potable water filtration). They 
are styrene copolymers beads with a small diameter and a 
large adsorption surface per bead (550 m2/g and 850 m2/g, 
respectively), rich in carbon and hydrogen molecules. It is 
being theorized that they interact with the other carbon and 
hydrogen atoms from molecules such as edoxaban, dabi-
gatran, or radiocontrast agents through hydrophobic van der 
Waals and hydrogen bonds [5]. CytoSorb has obtained the 
European Union approval for removal of cytokines during 
cardiopulmonary bypass in coronary artery bypass graft 
surgery [11].
One can imagine removing edoxaban clinically by means 
of hemadsorption (blood is passed directly through the sorb-
ent column) or hemodiadsorption, where hemodialysis is 
complemented by sorbent technology. In the latter scenario, 
the dialysate fluid is circulated and cleaned through the sorb-
ent while being pushed through the sorbent column by the 
dialysis machine pump, with no need of significant addi-
tional hardware.
Regarding the intra-venous access needed, one can use 
a central large-bore double-lumen catheter similar with a 
dialysis catheter or a central intra-venous line (internal jugu-
lar, subclavian, or femoral). Alternatively, one can employ 
a double-lumen, peripherally inserted central catheter. The 
latter may accommodate a 40-mL/min one-way suction out-
put. In general, a venous access can result in minor blood 
extravasation in anticoagulated patients but no significant 
hemorrhagic complications unless the operator cannulates 
by mistake an arterial conduit.
Patients could be simultaneously taking both antiplatelet 
and anticoagulant agents, such as during treatment for atrial 
fibrillation and coronary disease. As our method can remove 
both edoxaban and the P2Y12 antagonist ticagrelor, the 
hemadsorption route would be the most suitable in the case 
of a hemorrhage caused by this drug combination, where 
one could fit the patients with a dual lumen central line that 
would transfer that patient’s venous blood to and from a 
hemadsorption machine. A second clinical scenario where 
hemadsorption could be used is the possibility of removing 
the two drugs prior and during open-heart surgery, where 
blood is being circulated through a cardiopulmonary bypass 
machine, which would allow one to pass the former through 
a sorbent column. In a third but similar scenario, of vascu-
lar surgery, the blood is usually bypassed through a shunt 
to avoid bleeding in the area served by the artery operated 
on. The shunted blood can be directed to a sorbent column 
before being sent back to the patient.
We used 4% BSA solution because this value is simi-
lar to the physiologic albumin concentration. Fifty-five 
percent of edoxaban in plasma binds to proteins of which 
albumin is the major component. The remaining proteins, 
mostly globulins, interact with drugs through similar 
forces as albumin, hence we assumed in this experiment 
that BSA solution would behave in a similar manner as 
a mixture of albumin and globulins, allowing us to pool 
together the human plasma and BSA samples in some of 
our calculations.
It is important to note that sorbents can remove through 
hydrophobic bonds other drugs used in atrial fibrillation 
such as heart rate control agents, including beta-blockers or 
calcium channel blockers, [12] eventually resulting in the 
need to temporarily increase the dose of these two classes of 
drugs during the short adsorption process. Dialysis removes 
low quantities of edoxaban and ticagrelor [5, 7, 13, 14], likely 
because there is no active mechanism of retaining a drug with 
hemodialysis but just a passive equilibrium of the two sides 
separated by the dialysis membrane. Sorbent adsorption may 
have an advantage in this respect likely owing to the active 
mechanism of drug retention through van der Waals and 
hydrogen bonds [5].
While our study has investigated only edoxaban, a clini-
cal trial using CytoSorb showed improved outcomes in a 
population of patients treated with ticagrelor or rivaroxa-
ban and then undergoing sorbent-based drug removal during 
coronary artery bypass graft surgery [15], suggesting that 
hemadsorption could be used in a large portion of patients 
treated with factor Xa antagonists. In summary, sorbent-
mediated edoxaban removal has the potential of improv-
ing the clinical outcome or shortening the length of stay in 
patients anticoagulated with this agent and admitted with 
a hemorrhage or waiting to undergo urgent open-heart or 
vascular surgery.
4.2  Anti‑Xa Antidote Methods Tested Elsewhere
As an alternative to removal procedures, andexanet alfa and 
ciraparantag are two factor Xa inhibitor antagonists in vari-
ous stages of clinical and preclinical trials [2]. None of these 
drugs are directed against other types of anticoagulants or 
antiplatelet and radiocontrast agents [2]. In addition to these 
shortcomings, andexanet alfa tends to be expensive (between 
US$29,700 and US$59,400 for a treatment) and presents 
an 18% risk of thrombosis [16]. An alternative is the pro-
thrombin complex concentrate product, which may be used 
off-label for the treatment of life-threatening hemorrhaging 
and costs US$9695 per treatment [16]. While no good analy-
sis has been published to our knowledge for hemadsorption, 
one may eventually extrapolate its cost from hemodialysis 
data. Hemodialysis in a Medicare patient would cost approx-
imately US$9726/month or roughly US$810/session in the 
first year of dialysis [17]. To this amount, one may add the 
current cost of the sorbent at US$1000 for a 300-mL car-
tridge (CytoSorbents, data on file), to a total of US$1810, 
considerably lower than the cost of any of the two options 
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listed above. In the scenario where one uses a hemodiad-
sorption system, no additional hardware might be needed 
in addition to the dialysis machine as detailed previously. 
If a different machine might be needed for regular hemad-
sorption sessions, one may need to factor in the cost of that 
particular equipment.
4.3  Limitations
We used low velocities with the purpose of achieving opti-
mal removal targets in this first edoxaban removal study. By 
increasing the sorbent volume and adsorption velocity, we 
could reach in future studies faster removal times, possibly 
with a minor drop in the current removal rate values.
The discrepancy between the baseline target concentration 
of 100 ng/mL and resulting baseline values of 407 ± 216 ng/
mL (baseline average of all six samples) and 276.8 ng/mL 
(average of baseline human plasma) was likely a result of pos-
sible inconsistencies during the steps of weighing and diluting 
from a bulk sample of 8 mg of edoxaban. Nonetheless, these 
baseline values are higher than the target 100 ng/mL, offer-
ing a plus in the process of demonstrating the potency of our 
edoxaban sorbent removal method.
We used a relatively low number of samples. Further 
experiments may be needed to confirm our results. On the 
same note, further in-vivo studies will need to assess the 
return to an eventual normal coagulation status after edoxa-
ban removal.
5  Conclusions
Sorbents are efficient tools for robustly removing edoxaban 
during fast first-pass bench experiments using human plasma 
and BSA solutions.
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